FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours
per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																	
1. Name and Address of Reporting Person * MARIANI PETER J					2. Issuer Name and Ticker or Trading Symbol Axogen, Inc. [AXGN]							5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 13631 PROGRESS BOULEVARD, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 03/16/2022								X Officer (give title below) Other (specify below) EVP & Chief Financial Officer					
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
ALACHUA, FL 32615 (City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							es Acquire	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/	Year) E	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		(4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f(D) O	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form:	7. Nature of Indirect Beneficial	
				(1			Code	÷	V	Amount	(A) or (D)	Price				Ownership (Instr. 4)		
Common Stock 03/16/			03/16/2022	,			M			1,000 1)	A	\$ 0 3	7,353			D		
Common Stock			03/16/2022	;			F			2,769 <u>2)</u>	D	\$ 7.97 3	34,584		D			
			Table			tive Securit		th Cu ired,	nis fori urrent , Dispo	n are no y valid sed of, o	ot requi OMB co r Benefi	red to recontrol nu				SEC	1474 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transa Code	Transaction Derivative Securities		of 6. Date Expirati (Month/		Date Expiration	Exercisable and on Date 7.		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	Owners Form o Derivat Security Direct (Ownershi (Instr. 4)	
				Code	V	(A)	(D)	Dat Exe		Expira e Date	tion	Title	Amount or Number of Shares		Reported Transaction(s (Instr. 4)	or Indir (I) (Instr. 4		
Restricted Stock Units	(3)	03/16/2022		М			11,000		<u>(4)</u>		<u>(4)</u>	Commo	1 11 000 00	\$ 0	11,000	D		
Restricted Stock Units	(3)	03/16/2022		A		76,780			<u>(5)</u>		<u>(5)</u>	Commo	1 76 780 00	\$ 0	76,780	D		
Employee Stock Option (right to purchase)	\$ 10.25 (6)	03/16/2022		A		103,079			(7)	03/16	5/2032	Commo Stock	11030/900	\$ 0	103,079	D		

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
MARIANI PETER J 13631 PROGRESS BOULEVARD SUITE 400 ALACHUA, FL 32615			EVP & Chief Financial Officer					

Signatures

/s/Peter Mariani	03/18/2022			
***Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This reflects the number of restricted stock units that became vested as of March 16, 2022.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the (2) Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- (3) Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
- All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the (4) aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the
- (5) aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- (6) The exercise price of \$10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.
- (7) All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.